Northwest BiotherapeuticsNWBO
13F holders, Q2 2025 (June 30)9holders +1
1new positions
0sold out
$0.24avg. 13F price*
At the end of Q2 2025, 9 institutions reported holding Northwest Biotherapeutics (NWBO) in their 13F filings, up 1 from Q1 2025. 1 opened new positions and 0 sold out. The largest holders were Moloney Securities Asset Management, LLC ($120K), VSM Wealth Advisory, LLC ($16K) and Opus Capital Group, LLC ($14K).
- Company
- Northwest Biotherapeutics
- CUSIP
- 66737P600
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 27,790 shares bought, net +27,790 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Moloney Securities Asset Management, LLC | 0.01% | Add +0.3% | 501,560 | $120K |
| VSM Wealth Advisory, LLC | 0.01% | No change | 65,574 | $16K |
| Opus Capital Group, LLC | 0.00% | No change | 60,150 | $14K |
| Ethos Financial Group, LLC | 0.00% | Add +107.0% | 49,050 | $13K |
| Williams Jones Wealth Management, LLC. | 0.00% | No change | 27,000 | $6K |
| KLCM Advisors, Inc. | 0.00% | No change | 10,000 | $2K |
| Advisors Management Group Inc. | 0.00% | No change | 10,270 | $2K |
| Hantz Financial Services, Inc. | 0.00% | No change | 250 | $0 |
| Coston, McIsaac & Partners | 0.00% | New | 1,000 | $0 |
"% of holder's portfolio" is NWBO's weight in each manager's 13F, not the share of Northwest Biotherapeutics the manager owns.